Abstract
ABSTRACT
INTRODUCTION. To synthesize all available evidence on the effectiveness and vaccination coverage obtained in the target population of health systems that have initiated vaccination campaigns with the Shingrix® vaccine.
METHOD. Systematic review by means of a bibliographic search in the health sciences databases: Cochrane, PubMed, SCOPUS, Lilacs, IBECS, Scielo, ENFISPO and Dialnet. A critical reading of the studies was subsequently carried out using the Critical Appraisal Skills Programme guidelines, assessing quality and level of evidence with the Grading of Recommendations Assessment, Development and Evaluation Working Group and Scottish Intercollegiate Guidelines Network.
RESULTS. The review identified 190 articles among the indicated sources and included 17 articles with the established eligibility criteria. These studies show an effectiveness of 84.5% (R=83.5-85.5) and a vaccination coverage of 29% (R=3.6-69), with the reported one being 25% (R=16.6-32) and the recorded one being 29.9% (R=3.6-69).
discussion. Understanding vaccine effectiveness is crucial to understanding the differences between real results and those of clinical trials. The observed effectiveness was optimal and consistent, with vaccination coverage below the desirable objectives in the target population, which could be due to the recent introduction of the vaccine and the limited information provided.
CONCLUSIONS. The effectiveness was good and stable, regardless of age, sex, race-ethnicity and geographic region. Vaccination coverage was lower than the desired target, and it was necessary to consider the healthcare characteristics and socio-health determinants that influence the level of vaccination coverage in order to try to increase.
References
Salleras L, Salleras M. Vacunación frente al herpes zóster. Vacunas. 2014;15(1):146-69. Disponible en: https://doi.org/10.1016/S1576-9887(14)70075-5
Gómez Marco JJ, Vañó Garrido-Arroquia A, Fidalgo López A, Herpes zóster: prevención, diagnóstico y tratamiento. FMC: Formación Médica Continuada en Atención Primaria. 2023;30(7):337-44. Disponible en: https://doi.org/10.1016/j.fmc.2023.01.003
Molero JM, Ortega J, Montoro I, McCormick N. Estado actual del herpes zóster y las nuevas perspectivas para su prevención. Vacunas. 2024;25(2):254-63. Disponible en: https://doi.org/10.1016/j.vacun.2023.12.005
Molero-García JM, Moreno-Guillén S, Rodríguez-Artalejo F, Ruíz-Galiana J, Cantón R, De Lucas-Ramos P, et al. Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper. Rev Esp Quimioter. 2023;36(3):223-35. Disponible en: https://doi.org/10.37201/req/004.2023
Gómez-Marco JJ, Martín-Martín S, Aldaz-Herce P, Javierre-Miranda AP, Sánchez-Hernández C. Vacunación frente al virus del herpes zóster. Atención Primaria. 2023;55(1):1-9. Disponible en: https://doi.org/10.1016/j.aprim.2023.102710
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas. Rev Esp Cardiol. 2021;74(9):790-9. Disponible en: https://doi.org/10.1016/j.recesp.2021.06.016
Lu X, Lu J, Zhang L, Mei K, Guan B, Lu Y. Gap between willingness and behavior in the vaccination against influenza, pneumonia, and herpes zoster among Chinese aged 50–69 years. Expert review of vaccines. 2021;20(9):1147-52. Disponible en:
https://doi.org/10.1080/14760584.2021.1954910
Rome BN, Feldman WB, Fischer MA, Desai RJ, Avorn J. Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization. JAMA New Open. 2021;4(11):1-13. Disponible en: http://doi.org/10.1001/jamanetworkopen.2021.35362
Sun Y, Kim E, Kong CL, Arnold BF, Porco TC, Acharya NR. Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study. Clin Infect Dis. 2021;73(6):949-56. Disponible en: http://dx.doi.org/10.1093/cid/ciab121
Sun Y, Jackson K, Dalmon CA, Shapiro BL, Nie S, Wong C, et al. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study. Vaccine. 2021;39(29):3974-82. Disponible en: http://dx.doi.org/10.1016/j.vaccine.2021.05.056
Leung J, Anderson TC, Dooling K, Xie F, Curtis JR. Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults with Immune-Mediated Inflammatory Diseases in the US. Arthritis Rheumatol. 2022;74(11):1833-41. Disponible en: http://dx.doi.org/10.1002/art.42261
Leung J, Gray EB, Anderson TC, Sharkey SM, Dooling K. Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50–64 years in the United States. Vaccine. 2022;40(50):7187-90. Disponible en: https://doi.org/10.1016/j.vaccine.2022.10.065
Ricks T, Trent MJ, MacIntyre CR. Predictors of herpes zoster vaccination among Australian adults aged 65 and over. Vaccine. 2022;40(50):7182-6. Disponible en: https://doi.org/10.1016/j.vaccine.2022.10.064
Di Giuseppe G, Pelullo CP, Napoli A, Napolitano F. Willingness to receive Herpes Zoster vaccination among adults and older people: A cross sectional study in Italy. Vaccine. 2023;41(48):7244-9. Disponible en: http://dx.doi.org/10.1016/j.vaccine.2023.10.049
Krasselt M, Wagner UlF, Seifert O. Influenza, Pneumococcal and Herpes Zoster Vaccination Rates in Patients with Autoimmune Inflammatory Rheumatic Diseases. Vaccines. 2023;11(4):1-8. Disponible en: https://doi.org/10.3390/vaccines11040760
San-Tan P, Patone M, Clift AK, Dambha-Miller H, Saatci D, Ranger TA, et al. Factors influencing influenza, pneumococcal and shingles vaccine uptake and refusal in older adults: a population-based cross-sectional study in England. BMJ Open. 2023;13:1-10. Disponible en: https://doi.org/10.1136/bmjopen-2021-058705
Tsiligianni I, Bouloukaki I, Papazisis G, Paganas A, Chatzimanolis E, Kalatharas M, et al. Vaccination coverage and predictors of influenza, pneumococcal, herpes zoster, tetanus, measles, and hepatitis B vaccine uptake among adults in Greece. Public Health. 2023;224(1):195-202. Disponible en: https://doi.org/10.1016/j.puhe.2023.09.002
Avramidis I, Pagkozidis I, Domeyer PRJ, Papazisis G, Tirodimos I, Dardavesis T, et al. Exploring Perceptions and Practices Regarding Adult Vaccination against Seasonal Influenza, Tetanus, Pneumococcal Disease, Herpes Zoster and COVID-19: A Mixed-Methods Study in Greece, Vaccines. 2024;12(1):1-18. Disponible en: https://doi.org/10.3390/vaccines12010080
Ceccarelli A, Tamarri F, Angelini R, Bakken E, Concari I, Giannoccaro E, et al. Herpes Zoster Vaccine Uptake and Active Campaign Impact, a Multicenter Retrospective Study in Italy. Vaccines. 2024;12(1):1-11. Disponible en: https://doi.org/10.3390/vaccines12010051
Gilmour H. Factors associated with shingles and pneumococcal vaccination among older Canadians. Health Rep. 2024;35(1):14-24. Disponible en: https://doi.org/10.25318/82-003-x202400100002-eng
Kpozehouen EB, Macintyre CR, Tan TC. Determinants of uptake of influenza, zoster and pneumococcal vaccines in patients with cardiovascular diseases. Vaccine. 2024;42(15):3404-9. Disponible en: https://doi.org/10.1016/j.vaccine.2024.04.031
Rowley F, Cottrell S, Howard C, Meredith N, Song J, Barrasa A, et al. Use of invitations and reminders are associated with higher levels of Herpes zoster (shingles) vaccination uptake. A cross-sectional survey of general practices in Wales, and ecological analysis of uptake data 2022. Vaccine. 2024;42(7):1682-9. Disponible en: http://dx.doi.org/10.1016/j.vaccine.2024.02.034
Salussolia A, Capodici A, Scognamiglio F, La Fauci G, Soldà G, Montalti M, et al. Herpes zoster (HZ) vaccine coverage and confidence in Italy: a Nationwide cross-sectional study, the OBVIOUS project. BMC Infect Dis. 2024;24(1):438. Disponible en: http://dx.doi.org/10.1186/s12879-024-09344-7
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2026 RqR Quantitative and Qualitative Community Nursing Research